Who is sponsoring NCT03375762?

NCT03375762 is sponsored by Institut de Recerca Biomèdica de Lleida.

What drugs are being tested in NCT03375762?

Interventions in NCT03375762: Remote ischemic perconditioning, Sham remote perconditioning.

What condition does NCT03375762 study?

NCT03375762 studies Ischemic Stroke.

Is NCT03375762 still recruiting?

NCT03375762 is currently status unknown. Last updated 3 January 2024.

Last reviewed 2024-01-03 · How we verify

NCT03375762: REMOTE-CAT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients ( REMOTE-CAT)

Status unknown NA Last updated 3 January 2024

What this trial tests

NA trial testing Remote ischemic perconditioning in Ischemic Stroke in 572 participants. Status unknown.

Timeline

7 August 2019

Primary endpoint
15 March 2024

1 April 2024

Quick facts

Lead sponsor	Institut de Recerca Biomèdica de Lleida
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	health services research
Enrollment	572
Start date	7 August 2019
Primary completion	15 March 2024
Estimated completion	1 April 2024
Sites	1 location across Spain

Drugs / interventions tested

Remote ischemic perconditioning
Sham remote perconditioning

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

Institut de Recerca Biomèdica de Lleida

Who can join

18 and older, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Stroke is one of the leading causes of death worldwide and the main cause of incapacity. Currently, the only therapies for acute ischemic stroke (AIS) patients are the administration of recombinant tissue plasminogen activator (rt-PA) and/or endovascular treatment. Unfortunately, many patients cannot benefit from these therapies due to contraindications or evolution time. Neuroprotective therapies could not only increase the benefits of available reperfusion therapies but also provide an option for patients who are not candidates for these treatments. Remote ischemic conditioning, consisting on brief episodes of transient limb ischemia, represents a new paradigm in neuroprotection. It can be categorized in pre-, per- or postconditioning, depending on the moment of application. According to studies in coronary ischemia, remote ischemic perconditioning (RIPerC) during the ischemic event is safe, cost-effective, feasible and associated with a reduction in myocardial injury. The investigators aim to conduct a multicentre study (5 university hospitals) of pre-hospital RIPerC in AIS patients (within 8 hours of stroke onset), which would include 572 stroke code activated patients (286 would undergo RIPerC and 286 would be sham). Our hypothesis is that RIPerC would be safe and would induce endogenous neuroprotective phenomena associated with good outcomes in AIS patients whether treated with revascularization therapies or not. Moreover, the development of systemic ischemic tolerance should provide metabolomic and lipidomic signatures that would present an opportunity to find specific molecular markers (biomarkers). The main objectives will be to assess: 1) RIPerC clinical benefits in AIS, 2) whether RIPerC is safe not only in AIS but also in all cases of stroke code activation, 3) whether RIPerC is associated with a reduction in cerebral infarct size and 4) metabolomic and lipidomic signatures of the RIPerC effect.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.
Paul S, Candelario-Jalil E. · · 2021 · cited 531× · PMID 33144066 · DOI 10.1016/j.expneurol.2020.113518
Effect of In-Hospital Remote Ischemic Perconditioning on Brain Infarction Growth and Clinical Outcomes in Patients With Acute Ischemic Stroke: The RESCUE BRAIN Randomized Clinical Trial.
Pico F, Lapergue B, Ferrigno M, Rosso C, et al · · 2020 · cited 75× · PMID 32227157 · DOI 10.1001/jamaneurol.2020.0326
Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature.
Ghozy S, Reda A, Varney J, Elhawary AS, et al · · 2022 · cited 51× · PMID 35711268 · DOI 10.3389/fneur.2022.870141
Remote ischemic conditioning for stroke: clinical data, challenges, and future directions.
Zhao W, Li S, Ren C, Meng R, et al · · 2019 · cited 45× · PMID 30656197 · DOI 10.1002/acn3.691
Remote but not Distant: a Review on Experimental Models and Clinical Trials in Remote Ischemic Conditioning as Potential Therapy in Ischemic Stroke.
Mollet I, Marto JP, Mendonça M, Baptista MV, et al · · 2022 · cited 25× · PMID 34686988 · DOI 10.1007/s12035-021-02585-6
Remote Ischemic Conditioning May Improve Disability and Cognition After Acute Ischemic Stroke: A Pilot Randomized Clinical Trial.
Poalelungi A, Tulbă D, Turiac E, Stoian D, et al · · 2021 · cited 21× · PMID 34526950 · DOI 10.3389/fneur.2021.663400
Induced neuroprotection by remote ischemic perconditioning as a new paradigm in ischemic stroke at the acute phase, a systematic review.
Purroy F, García C, Mauri G, Pereira C, et al · · 2020 · cited 19× · PMID 32615939 · DOI 10.1186/s12883-020-01836-8
Remote ischaemic conditioning for stroke: unanswered questions and future directions.
Baig S, Moyle B, Nair KPS, Redgrave J, et al · · 2021 · cited 15× · PMID 33903181 · DOI 10.1136/svn-2020-000722

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Institut de Recerca Biomèdica de Lleida trials

Trials by the same sponsor.

NCT06226194 — Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery · recruiting
NCT06083363 — Longitudinal Recovery Trajectories After an Acute Respiratory Distress Syndrome, a New Understanding · recruiting
NCT04746157 — A Nursing Support Intervention-based Project for Stroke Survivors · NA · completed
NCT03791008 — Assessment of Feasibility and Acceptability of Personalized Breast Cancer Screening · NA · completed
NCT03915522 — Adductor Canal Block in an Enhanced Recovery Program After Total Knee Arthroplasty · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03375762 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut de Recerca Biomèdica de Lleida
Last refreshed: 3 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03375762.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing